TIDMPEBI
RNS Number : 7010I
Port Erin Biopharma Investments Ltd
30 March 2015
Port Erin Biopharma Investments Limited 30 March 2015
("Port Erin" or the "Company")
Interim Results for the six month period ending 31 December
2014
The Board of Port Erin, the AIM quoted company focussed on
investing in the biotechnology and biopharmaceutical sectors, is
pleased to announce its interim results for the six month period
ending 31 December 2014.
The interim financial statements are expected to be available
from 30 March 2015 on the Company's website
http://www.porterinbiopharma.com/financial_reports.php.
Financial Highlights
As at 31 December 2014
Shareholders' Funds GBP4,838,038
Ordinary Shares in Issue 33,864,836
Net Asset Value per share 14.3 pence
Share Price * 11.0 pence
Share Price Discount (30.0%)
* Mid-market closing price as at 25 March 2015.
Commenting on the results, Jim Mellon, Non-Executive Chairman of
Port Erin, said: "The Company's three significant investments
continue to show substantial growth potential for the remainder of
2015 and beyond. In addition, your board is currently considering a
number of exciting options which show considerable promise in line
with the investing policy adopted on 11 November 2013."
For further information, please contact:-
Port Erin Biopharma Investments Limited
Denham Eke (+44) (0) 1624 639396
Beaumont Cornish Limited
Roland Cornish / James Biddle (+44) (0) 207 628 3396
Peterhouse Corporate Finance Limited
Lucy Williams (+44) (0) 20 7469 0936
Chairman's statement
Introduction
I am pleased to present the Interim Results for Port Erin
Biopharma Investments Limited (the "Company") for the six month
period ending 31 December 2014.
The results should be viewed against the backdrop of
facilitating the tender offer, as announced on 14 January 2015,
which gave shareholders the opportunity to sell a proportion of
their holding back to the Company at the implicit value rather than
the historically discounted market price (the "Tender Offer").
Shareholders will recall that this was one of the steps identified
to allow access to the true value of the proportion of their
holding represented by the investment in the Magna Biopharma Income
Fund ("MBIF"), following a strategic review to help eliminate the
significant discount to Net Asset Value implicit in the Company's
share price.
Following the successful completion of the tender offer in
February 2015 which saw a shareholder uptake of 50.68 per cent.,
the Company still retains a significant investment in MBIF whose
investment objective is to seek growing income distributions with
capital appreciation potential in the long term by investing in a
diversified portfolio of biopharma sector securities. The
investment prospects for MBIF remain compelling and the share price
has already grown by over 10 per cent. during the first two months
of 2015.
Aside from MBIF, the Company has two other significant
investments, namely Plethora Solutions Holdings plc ("Plethora")
and Summit Corporation plc ("Summit"). Plethora reported on 11
November 2014 that it continues to make good progress in
commercialising FORTACIN(TM), a treatment and management for
urological disorders, and expects to complete the New Drug
Application filing and potential approval during Q4 2015. Based on
estimated market sizes, pricing input from its US marketing
consultant and other internal estimates, the Directors of Plethora
believe forecast peak prescription sales (end user sales) could
reach in excess of US$1 billion per annum for FORTACIN(TM).
Summit is an international biopharmaceutical company focussed on
the discovery and development of innovative medicines to treat the
fatal muscle wasting disease Duchenne Muscular Dystrophy ("DMD")
and infections caused by the bacteria C. difficile ("CDI"). Summit
is seeking to rapidly advance the development of its lead product
candidates, SMT C1100 for DMD and SMT19969 for CDI, through patient
clinical trials with the goal of seeking to maximise the commercial
opportunity for each of these candidates, including potentially by
entering into collaborative arrangements with third parties or by
retaining commercialisation rights for itself.
Financial Review
The Company recorded a net loss of GBP143,388 for the half-year
interim period (31 December 2013: profit of GBP1,787,086). During
the period, our investment income including dividends, net realised
gains on sales, and net unrealised gains was GBP83,835 (31 December
2013: GBP2,340,447). In the prior period significant unrealised
gains were booked against the investments of Summit and Plethora
following the initial acquisition which were not repeated in the
current period. Operating expenses were GBP227,223 (31 December
2013: GBP553,384). The prior period included a performance fee due
of GBP379,057 following the uplift in net assets. No performance
fee has been accrued in the current period.
The net loss of GBP143,388 for the period was reflected in the
basic and diluted loss per share of 0.42 pence (31 December 2013:
earnings of 5.28 pence).
Our invested assets at fair value at 31 December 2014 were
GBP4,468,412 (30 June 2014: GBP4,830,908), and cash and equivalents
were GBP431,744 (30 June 2014: GBP526,503). Including receivables
of GBP13,739 (30 June 2014: GBP24,997) less payables of GBP75,857
(30 June 2014: GBP400,982), our total net assets stood at
GBP4,838,038 (30 June 2014: GBP4,981,426). Thus as a result of the
loss of GBP143,388 for the period the net asset value of the
Company has decreased, and this is reflected in the net asset value
per share at 31 December 2014 of 14.3 pence (30 June 2014: 14.7
pence).
Post period end and as a result of the Tender Offer, the Company
completed the sale and transfer of 163,341.177 MBIF shares
(representing 50.38 per cent. of the Company's total holding of
MBIF shares). The net proceeds, after expenses, from the sale of
116,635.177 MBIF shares amounted to GBP1,202,269 being distributed
to Shareholders in cash, with the remaining 46,706 MBIF shares to
be distributed in specie to Shellbay Investments Limited by way of
consideration.
Strategy and Outlook
Whilst the results for the present period have reported losses,
positive steps have been taken in addressing the significant
discount to Net Asset Value implicit in the Company's share price
mentioned above which we firmly believe will enhance shareholder
value in the future.
The Company's three significant investments continue to show
substantial growth potential for the remainder of 2015 and beyond.
In addition, your board is currently considering a number of
exciting options which show considerable promise in line with the
investing policy adopted on 11 November 2013.
Jim Mellon
Chairman
Condensed statement of comprehensive income
Period Period
ended ended
31/12/2014 31/12/2013
Notes (unaudited) (unaudited)
GBP GBP
------------------------------------- ------- ------------- -------------
Investment Income 2 83,835 2,340,447
Operating expenses
Performance fee 3 - (379,057)
Other costs 4 (269,234) (100,509)
Foreign exchange gains/(losses) 42,011 (73,818)
Operating (loss)/profit (143,388) 1,787,063
Interest received - 23
(Loss)/profit before taxation (143,388) 1,787,086
Taxation - -
(Loss)/profit for the period (143,388) 1,787,086
Other comprehensive income - -
Total comprehensive (loss)/income
for the period (143,388) 1,787,086
------------------------------------- ------- ------------- -------------
Basic and diluted (loss)/earnings
per share for (loss)/profit
attributable to the equity
holders of the Company during
the period (pence) 5 (0.42) 5.28
------------------------------------- ------- ------------- -------------
Condensed statement of financial position
31/12/2014 30/06/2014
Notes (unaudited) (audited)
GBP GBP
-------------------------------- ------- ------------- -----------
Current assets
Financial assets at fair value
through profit or loss 6 4,468,412 4,830,908
Trade and other receivables 13,739 24,997
Cash and cash equivalents 431,744 526,503
Total assets 4,913,895 5,382,408
Equity
Called up share capital 34 34
Share premium 2,759,551 2,759,551
Distributable reserves 2,078,453 2,221,841
Total equity 4,838,038 4,981,426
Current liabilities
Trade and other payables 7 75,857 400,982
Total liabilities 75,857 400,982
Total equity and liabilities 4,913,895 5,382,408
Condensed statement of changes in equity
Share Share Distributable
capital premium reserves Total
Notes GBP GBP GBP GBP
-------------------------- --------- --------- ------------ -------------- ------------
Balance at 01 July
2013 (audited) 34 2,759,551 840,366 3,599,951
Total comprehensive
income for the period:
Profit for the period - - 1,787,086 1,787,086
Other comprehensive - - - -
income
Balance at 31 December
2013 (unaudited) 34 2,759,551 2,627,452 5,387,037
------------------------------------- --------- ------------ -------------- ------------
Balance at 01 July
2014 (audited) 34 2,759,551 2,221,841 4,981,426
Total comprehensive
income for the period:
Loss for the period - - (143,388) (143,388)
Other comprehensive - - - -
income
Balance at 31 December
2014 (unaudited) 34 2,759,551 2,078,453 4,838,038
--------------------------- ----- ------------ ------------ ------------
Condensed statement of cash flows
Period Period
ended ended
Notes 31/12/ 2014 31/12/2013
(unaudited) (unaudited)
GBP GBP
-------------------------------------- -------- ------------- ------------
Cash flows from operating activities
(Loss)/profit for the period (143,388) 1,787,086
Adjusted for:
Interest received - (23)
Realised and unrealised gains 2 (83,835) (2,338,021)
Performance fee settled by transfer 379,053 -
of investment
Changes in working capital:
Decrease in receivables 11,258 2,691
(Decrease)/increase in payables (325,125) 379,515
Cash flows from operations (162,037) (168,752)
Cash flows from investing activities
Purchase of investments - (3,395,510)
Proceeds from sale of investments 67,278 3,659,356
Interest received - 23
Net cash generated from investing
activities 67,278 263,869
(Decrease)/increase in cash and
cash equivalents (94,759) 95,117
Cash and cash equivalents at
beginning of period 526,503 707,624
Cash and cash equivalents at
the end of period 431,744 802,741
Notes to the financial statements
1 Significant accounting policies
The accounting policies adopted by the Company in the
preparation of these condensed interim financial statements are the
same as those applied by the Company in its financial statements as
at and for the year ended 30 June 2014. No new accounting policies
were adopted during the period.
The interim financial statements are unaudited. The audited
financial statements of the Company as at and for the year ended 30
June 2014 are available at the Company's website below:
http://www.porterinbiopharma.com/financial_reports.php
2 Investment income
31/12/2014 31/12/2013
(unaudited) (unaudited)
GBP GBP
-------------------------------------- ------------- ----------------
Dividend income - 2,426
Net realised gains on sale of
investments 34,961 966,330
Net unrealised gains on investments 48,874 1,371,691
Total investment income 83,835 2,340,447
-------------------------------------- ------------- ----------------
3 Performance fee
31/12/2014 31/12/2013
(unaudited) (unaudited)
GBP GBP
-------------------------- -------------- ----------------
Performance fee - 379,057
-------------------------- -------------- ----------------
Shellbay Investments Limited ("Shellbay") receive performance
fees for the provision of Mr James Mellon, Non-Executive Chairman
of the Company, in respect of investment advisory services. The
fees are calculated at 15 per cent. of any increase in the net
asset value of the Company over each quarterly period (excluding
MBIF), subject to an initial high watermark of 10 pence per share.
The calculation base excludes the MBIF investment as Shellbay do
not provide any investment advice in relation to that holding. No
fees were payable for the current period (31 December 2013:
GBP379,057).
4 Other costs
31/12/2014 31/12/2013
(unaudited) (unaudited)
GBP GBP
--------------------------------- ------------- -------------
Directors' fees 2,810 7,233
Auditors' remuneration for the
current period 7,500 8,625
Bank charges 104 209
Insurance 2,690 3,193
Marketing - 3,575
Professional fees 253,581 77,299
Sundry expenses 2,549 375
Total other costs 269,234 100,509
--------------------------------- ------------- -------------
5 Basic and diluted earnings per share
The calculation of basic earnings per share of the Company is
based on the loss for the period of GBP143,388 (31 December 2013:
profit of GBP1,787,086) and the weighted average number of shares
of 33,864,836 (31 December 2013: 33,864,836) in issue during the
period.
Diluted earnings per share are calculated by adjusting the
weighted average number of ordinary shares outstanding to assume
conversion of all dilutive potential ordinary shares such as
warrants and options. There is no dilutive effect in the current or
prior period as there were no outstanding warrants or options.
6 Financial assets at fair value through profit or loss
31/12/2014 30/06/2014
(unaudited) (audited)
GBP GBP
----------------------------------- ------------- ------------
Quoted 4,060,987 4,454,788
Unquoted 407,425 376,120
Total financial assets at fair
value 4,468,412 4,830,908
----------------------------------- ------------- ------------
Equities 4,293,174 4,684,117
Warrants 175,238 146,791
Total financial assets at fair
value 4,468,412 4,830,908
----------------------------------- ------------- ------------
7 Trade and other payables
31/12/2014 30/06/2014
(unaudited) (audited)
GBP GBP
----------------------------------- ------------ -----------
Provision for audit fee 7,500 15,000
Related party - Shellbay - 379,057
Other 68,357 6,925
Total trade and other payables 75,857 400,982
----------------------------------- ------------ -----------
8 Related party transactions
Under an agreement dated 1 December 2011, Burnbrae Limited, a
company related to both Mr James Mellon and Mr Denham Eke, provide
certain services, principally accounting and administration, to the
Company. This agreement may be terminated by either party on three
months' notice. The Company incurred a total cost of GBP18,000 (31
December 2013: GBP18,000) during the period under this agreement of
which GBPnil was outstanding as at the period end (30 June 2014:
GBPnil).
Under an agreement dated 6 May 2011 Shellbay, a company related
to both Mr James Mellon and Mr Denham Eke, provide the services of
Mr James Mellon as Non-Executive Chairman of the Company (see note
3). The charge for services provided in the period was GBPnil (31
December 2013: GBP379,057), of which GBPnil was outstanding at the
period-end (30 June 2014: GBP379,057).
9 Commitments and contingent liabilities
There are no known commitments or contingent liabilities as at
the period end.
10 Events after the reporting date
Subject to the terms of a tender offer (the "Tender Offer") in
respect of the Company's interest in the Magna Biopharma Income
Fund set out in a circular (the "Circular") dated 13 January 2015,
the Company received acceptances in respect of up to 17,164,238
shares ("Eligible Shares") of the Company, representing in
aggregate 50.68 per cent. of the issued share capital.
As specified in the market announcement dated 6 February 2015
detailing the close of the Tender Offer, the Tender Entitlement (as
defined in the Circular) of each shareholder accepting the Tender
Offer was accordingly set at 62.16 per cent. of Eligible Shares.
Consequently, on completion of the Tender Offer, the Company
redeemed and cancelled in aggregate 10,669,278 shares (the "Tender
Shares").
On 5 February 2015, the Company completed the sale and transfer
of 163,341.177 Fund Shares (as defined in the Circular)
(representing 50.38 per cent. of the Company's total holding of
Fund Shares). The net proceeds, after expenses, from the sale of
116,635.177 Fund Shares amounted to GBP1,202,269 being distributed
in cash, with the remaining 46,706 Fund Shares to be distributed in
specie to Shellbay by way of consideration. Thus, the Tender Price
(as defined in the Circular) for each Tender Share (taking into
account the expenses of the Tender Offer) was set at GBP0.1587
(15.87 pence).
After payment of pro rata costs, Mr James Mellon and any related
parties will be transferred 46,706 Fund Shares by the Company by
way of consideration for the tender of 3,095,563 shares of the
Company by Mr Mellon and any related parties. Mr Mellon remains
interested in 6,729,273 shares, maintaining his shareholding at
29.01 per cent. of the issued shares.
Following completion of the Tender Offer the Company has a total
of 23,195,558 issued shares.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR FMGZFMNLGKZM
Agronomics (LSE:ANIC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agronomics (LSE:ANIC)
Historical Stock Chart
From Jul 2023 to Jul 2024